Keep up to date on the latest news and industry opinions on the biosimilar topics that matter to patients, providers, and payers.
Healthcare professionals in the EU and US still have a cautious approach towards using biosimilars in clinical practice because of concerns …
Read more
The number of approvals for biosimilar products is steadily increasing in Europe, the USA and other regions to combat the economic burden of…
Biosimilars are defined by the European Medicines Agency as high-quality biological drugs that are highly similar to and show no clinically …
Many European states have adopted strategies to balance their national budgets with special focus on healthcare, because of the financial an…
A look at the interests of various stakeholders and how biopharmaceutical companies are taking on the challenge of biosimilars reveals a com…
A quick guide to biosimilar medicines, how they’re made, and why you can trust them to be safe and effective.